ANDA 218350, held by Dr Reddys. Nilotinib Hydrochloride.
As of Nov 16, 2026, ANDA 218350 (Nilotinib Hydrochloride), held by Dr Reddys, was first approved by FDA on Nov 19, 2025, with 0 approved supplements and 0 published complete response letters.
Nilotinib is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 19, 2025 | Original application | Approved |
| Nilotinib HydrochlorideEQ 50MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
| Nilotinib HydrochlorideEQ 150MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
| Nilotinib HydrochlorideEQ 200MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters